NGM — NGM Biopharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $128.53m
- -$15.65m
- $4.42m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.86 | ||
| Price to Tang. Book | 0.86 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 29.1 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -101.8% | ||
| Return on Equity | -69.76% | ||
| Operating Margin | -3429.09% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 103.54 | 87.37 | 77.88 | 55.33 | 4.42 | 0.12 | n/a | -47.3% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
NGM Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company's biology-driven and therapeutic area agnostic discovery engine has produced a diverse pipeline of product candidates spanning oncology, liver and metabolic disease and retinal disease. Its pipeline candidates include NGM707: ILT2/ILT4 Dual Antagonist Antibody for the Potential Treatment of Solid Tumors, Including microsatellite stable colorectal cancer patients; Aldafermin: Engineered Analog of Human Hormone FGF19 for the Potential Treatment of primary sclerosing cholangitis, and NGM120: glial cell-derived neurotrophic factor receptor alpha-like Antagonist for the Potential Treatment of Hyperemesis Gravidarum. It is conducting an open-label Phase 1/2 clinical trial evaluating NGM707 as a monotherapy and in combination with pembrolizumab for the treatment of patients with advanced or metastatic solid tumors. Its programs, NGM438 and NGM831, are being studied in a Phase 1/2 trial in combination with pembrolizumab.
Directors
- William Rieflin CHM (61)
- David Woodhouse CEO (51)
- Jin-Long Chen FDR (58)
- Siobhan Mangini CFO (40)
- Valerie Pierce SVP (58)
- Alex Depaoli SVP
- Hsiao Lieu SVP (50)
- Wenyan Shen SVP
- Hui Tian SVP
- Marc Learned VOP
- David Goeddel LED (69)
- Shelly Guyer IND (60)
- Carole Ho IND (48)
- Suzanne Hooper IND (55)
- Mark Leschly IND (52)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 20th, 2007
- Public Since
- April 4th, 2019
- No. of Shareholders
- 33
- No. of Employees
- 138
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 83,462,408
- Address
- 333 Oyster Point Blvd, SOUTH SAN FRANCISCO, 94080-1978
- Web
- https://www.ngmbio.com/
- Phone
- +1 6502435555
- Auditors
- Ernst & Young LLP
Upcoming Events for NGM
NGM Biopharmaceuticals Inc Annual Shareholders Meeting
Q2 2024 NGM Biopharmaceuticals Inc Earnings Release
Similar to NGM
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the NGM Biopharmaceuticals share price?
As of Today at 19:15 UTC, shares in NGM Biopharmaceuticals are trading at $1.54. This share price information is delayed by 15 minutes.
How has the NGM Biopharmaceuticals share price performed this year?
Shares in NGM Biopharmaceuticals last closed at $1.54 and the price had moved by -60.81% over the past 365 days. In terms of relative price strength the NGM Biopharmaceuticals share price has underperformed the S&P500 Index by -69.06% over the past year.
What are the analyst and broker recommendations for NGM Biopharmaceuticals?
The overall consensus recommendation for NGM Biopharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the NGM Biopharmaceuticals dividend yield?
NGM Biopharmaceuticals does not currently pay a dividend.
Does NGM Biopharmaceuticals pay a dividend?
NGM Biopharmaceuticals does not currently pay a dividend.
When does NGM Biopharmaceuticals next pay dividends?
NGM Biopharmaceuticals does not currently pay a dividend.
How do I buy NGM Biopharmaceuticals shares?
To buy shares in NGM Biopharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of NGM Biopharmaceuticals?
As of the previous close price of $1.54, shares in NGM Biopharmaceuticals had a market capitalisation of $128.53m.
Where are NGM Biopharmaceuticals shares listed?
Here are the trading details for NGM Biopharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: NGM
What kind of share is NGM Biopharmaceuticals?
Based on an overall assessment of its quality, value and momentum NGM Biopharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a NGM Biopharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in NGM Biopharmaceuticals is $1.66. That is 7.79% above the last closing price of $1.54.
Analysts covering NGM Biopharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$1.27 for the next financial year.
Find out moreWhat is the trend in the NGM Biopharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like NGM Biopharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +0.23%.
As of the last closing price of $1.54, shares in NGM Biopharmaceuticals were trading -0.15% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the NGM Biopharmaceuticals PE Ratio?
The NGM Biopharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.54.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of NGM Biopharmaceuticals?
NGM Biopharmaceuticals' management team is headed by:
- William Rieflin - CHM
- David Woodhouse - CEO
- Jin-Long Chen - FDR
- Siobhan Mangini - CFO
- Valerie Pierce - SVP
- Alex Depaoli - SVP
- Hsiao Lieu - SVP
- Wenyan Shen - SVP
- Hui Tian - SVP
- Marc Learned - VOP
- David Goeddel - LED
- Shelly Guyer - IND
- Carole Ho - IND
- Suzanne Hooper - IND
- Mark Leschly - IND